Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology

Overview

Journal Curr Alzheimer Res

Publisher Bentham Science Publishers

Specialty Neurology

Date 2015 Dec 15

PMID 26651341

Citations 125

Authors

Elizabeth Head

Ira T Lott

Donna M Wilcock

Cynthia A Lemere

Affiliations

Soon will be listed here.

Abstract

Chromosome 21, triplicated in Down Syndrome, contains several genes that are thought to play a critical role in the development of AD neuropathology. The overexpression of the gene for the amyloid precursor protein (APP), on chromosome 21, leads to early onset beta-amyloid (Aβ) plaques in DS. In addition to Aβ accumulation, middle-aged people with DS develop neurofibrillary tangles, cerebrovascular pathology, white matter pathology, oxidative damage, neuroinflammation and neuron loss. There is also evidence of potential compensatory responses in DS that benefit the brain and delay the onset of dementia after there is sufficient neuropathology for a diagnosis of AD. This review describes some of the existing literature and also highlights gaps in our knowledge regarding AD neuropathology in DS. It will be critical in the future to develop networked brain banks with standardized collection procedures to fully characterize the regional and temporal pathological events associated with aging in DS. As more information is acquired regarding AD evolution in DS, there will be opportunities to develop interventions that are age-appropriate to delay AD in DS.

Citing Articles

Calcineurin inhibition may prevent Alzheimer disease in people with Down syndrome.

Dohl J, Treadwell Z, Norris C, Head E Alzheimers Dement. 2025; 21(3):e70034.

PMID: 40042516 PMC: 11881635. DOI: 10.1002/alz.70034.

Comparison of the amyloid plaque proteome in Down syndrome, early-onset Alzheimer's disease, and late-onset Alzheimer's disease.

Marta-Ariza M, Leitner D, Kanshin E, Suazo J, Giusti Pedrosa A, Thierry M Acta Neuropathol. 2025; 149(1):9.

PMID: 39825890 PMC: 11742868. DOI: 10.1007/s00401-025-02844-z.

Neuropathology of trisomy 21 mosaicism in a case with early-onset dementia.

Ngo P, Pascual J, Wright S, Williams C, Magaki S, Yong W Alzheimers Dement. 2024; 21(1):e14394.

PMID: 39655579 PMC: 11772706. DOI: 10.1002/alz.14394.

Down syndrome frontal cortex layer III and layer V pyramidal neurons exhibit lamina specific degeneration in aged individuals.

Alldred M, Ibrahim K, Pidikiti H, Chiosis G, Mufson E, Stutzmann G Acta Neuropathol Commun. 2024; 12(1):182.

PMID: 39605035 PMC: 11603868. DOI: 10.1186/s40478-024-01891-z.

Clinical and research application of fluid biomarkers in autosomal dominant Alzheimer's disease and Down syndrome.

Carmona-Iragui M, OConnor A, Llibre-Guerra J, Lao P, Ashton N, Fortea J EBioMedicine. 2024; 108:105327.

PMID: 39366843 PMC: 11663788. DOI: 10.1016/j.ebiom.2024.105327.

References

Zigman W . Atypical aging in Down syndrome. Dev Disabil Res Rev. 2013; 18(1):51-67. DOI: 10.1002/ddrr.1128. View

Lemere C, Blusztajn J, Yamaguchi H, Wisniewski T, Saido T, Selkoe D . Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis. 1996; 3(1):16-32. DOI: 10.1006/nbdi.1996.0003. View

Mann D, Iwatsubo T . Diffuse plaques in the cerebellum and corpus striatum in Down's syndrome contain amyloid beta protein (A beta) only in the form of A beta 42(43). Neurodegeneration. 1996; 5(2):115-20. DOI: 10.1006/neur.1996.0017. View

Westerman M, Mariash A, Kotilinek L, Kawarabayashi T, Younkin L, Carlson G . The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci. 2002; 22(5):1858-67. PMC: 6758862. View

Barbiero L, Benussi L, Ghidoni R, Alberici A, Russo C, Schettini G . BACE-2 is overexpressed in Down's syndrome. Exp Neurol. 2003; 182(2):335-45. DOI: 10.1016/s0014-4886(03)00049-9. View

Cataldo A, Peterhoff C, Troncoso J, Gomez-Isla T, Hyman B, Nixon R . Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am J Pathol. 2000; 157(1):277-86. PMC: 1850219. DOI: 10.1016/s0002-9440(10)64538-5. View

Ikeda S, Tokuda T, Yanagisawa N, Kametani F, Ohshima T, Allsop D . Variability of beta-amyloid protein deposited lesions in Down's syndrome brains. Tohoku J Exp Med. 1994; 174(3):189-98. DOI: 10.1620/tjem.174.189. View

Martin S, Dowling A, Lianekhammy J, Lott I, Doran E, Murphy M . Synaptophysin and synaptojanin-1 in Down syndrome are differentially affected by Alzheimer's disease. J Alzheimers Dis. 2014; 42(3):767-75. PMC: 4392817. DOI: 10.3233/JAD-140795. View

Hussain I, Powell D, Howlett D, Chapman G, Gilmour L, Murdock P . ASP1 (BACE2) cleaves the amyloid precursor protein at the beta-secretase site. Mol Cell Neurosci. 2000; 16(5):609-19. DOI: 10.1006/mcne.2000.0884. View

10.

Cummings B . Plaques and tangles: searching for primary events in a forest of data. Neurobiol Aging. 1997; 18(4):358-62; discussion 389-92. DOI: 10.1016/s0197-4580(97)00049-3. View

11.

Donahue J, Khurana J, Adelman L . Intracerebral hemorrhage in two patients with Down's syndrome and cerebral amyloid angiopathy. Acta Neuropathol. 1998; 95(2):213-6. DOI: 10.1007/s004010050789. View

12.

Head E, Johnson J, Lott I, Cotman C, Glabe C . Oxidation of Abeta and plaque biogenesis in Alzheimer's disease and Down syndrome. Neurobiol Dis. 2001; 8(5):792-806. DOI: 10.1006/nbdi.2001.0431. View

13.

Bittles A, Bower C, Hussain R, Glasson E . The four ages of Down syndrome. Eur J Public Health. 2006; 17(2):221-5. DOI: 10.1093/eurpub/ckl103. View

14.

Butterfield D, Di Domenico F, Swomley A, Head E, Perluigi M . Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: overlaps in Down's syndrome and Alzheimer's disease brain. Biochem J. 2014; 463(2):177-89. PMC: 4686233. DOI: 10.1042/BJ20140772. View

15.

Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole G . Inflammation and Alzheimer's disease. Neurobiol Aging. 2000; 21(3):383-421. PMC: 3887148. DOI: 10.1016/s0197-4580(00)00124-x. View

16.

Hartley D, Blumenthal T, Carrillo M, DiPaolo G, Esralew L, Gardiner K . Down syndrome and Alzheimer's disease: Common pathways, common goals. Alzheimers Dement. 2014; 11(6):700-9. PMC: 4817997. DOI: 10.1016/j.jalz.2014.10.007. View

17.

Jones E, Hanney M, Francis P, Ballard C . Amyloid beta concentrations in older people with Down syndrome and dementia. Neurosci Lett. 2008; 451(2):162-4. DOI: 10.1016/j.neulet.2008.12.030. View

18.

Lambert M, Barlow A, Chromy B, Edwards C, Freed R, Liosatos M . Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998; 95(11):6448-53. PMC: 27787. DOI: 10.1073/pnas.95.11.6448. View

19.

Schliebs R, Arendt T . The cholinergic system in aging and neuronal degeneration. Behav Brain Res. 2010; 221(2):555-63. DOI: 10.1016/j.bbr.2010.11.058. View

20.

Head E, Doran E, Nistor M, Hill M, Schmitt F, Haier R . Plasma amyloid-β as a function of age, level of intellectual disability, and presence of dementia in Down syndrome. J Alzheimers Dis. 2010; 23(3):399-409. PMC: 3219221. DOI: 10.3233/JAD-2010-101335. View